Opinion|Videos|June 27, 2024
Insights on T-DXd and Emerging Research on ADCs in HR+/HER2-Low Breast Cancer
Author(s)Aditya Bardia, MD, MPH, Laura Huppert, MD
Laura Huppert, MD, and Aditya Bardia, MD, MPH, FASCO, share advice for community oncologists on the utilization of T-DXd and discuss the future outlook for antibody-drug conjugates in HR+/HER2-low breast cancer.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- What advice can you share for community oncologists who are using T-DXd in their practice?
- What does the future look like for ADCs in HR+/HER2-low breast cancer?
Advertisement
Related to this article
Rural breast cancer deaths rise faster than urban rates, driven by low income, later diagnosis, and treatment gaps—warning of widening disparities by 2035.
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
3
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
4
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
5